Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients

Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma

(2012) Harkanwal Halait et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

KIT amplification and gene mutations in acral/mucosal melanoma in Korea

(2011) JINA YUN et al.   APMIS

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma

(2011) J. J. Luke et al.   CLINICAL CANCER RESEARCH

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAF targeted therapy changes the treatment paradigm in melanoma

(2011) Antoni Ribas et al.   Nature Reviews Clinical Oncology

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

(2011) Bianca Devitt et al.   Pigment Cell & Melanoma Research

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site

(2011) Jürgen Bauer et al.   Pigment Cell & Melanoma Research

Detection of Somatic Mutations by High-Resolution DNA Melting (HRM) Analysis in Multiple Cancers

(2011) Jesus Gonzalez-Bosquet et al.   PLoS One

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

(2010) J.-H. Lee et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

(2010) J. A. Ellerhorst et al.   CLINICAL CANCER RESEARCH

MC1R variants increase melanoma risk in families with CDKN2A mutations: A meta-analysis

(2010) Maria Concetta Fargnoli et al.   EUROPEAN JOURNAL OF CANCER

Association between the Germline MC1R Variants and Somatic BRAF/NRAS Mutations in Melanoma Tumors

(2010) Dominique Scherer et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Genetic and morphologic features for melanoma classification

(2010) Sigrid M. C. Broekaert et al.   Pigment Cell & Melanoma Research

Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls

(2009) Y.-m. Chang et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Relationship between Germline MC1R Variants and BRAF-Mutant Melanoma in a North Carolina Population-Based Study

(2009) Nancy E. Thomas et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Association between MC1R Genotype and BRAF Mutation Status in Cutaneous Melanoma: Findings from an Australian Population

(2009) Elke Hacker et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type

(2009) Carlos A Torres-Cabala et al.   MODERN PATHOLOGY

MC1R Variants Increase Risk of Melanomas Harboring BRAF Mutations

(2008) Maria Concetia Fargnoli et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation

(2008) Tiziana Venesio et al.   MODERN PATHOLOGY

Improving Melanoma Classification by Integrating Genetic and Morphologic Features

(2008) Amaya Viros et al.   PLOS MEDICINE